Send to

Choose Destination
Chem Biol Drug Des. 2019 Sep;94(3):1672-1679. doi: 10.1111/cbdd.13570. Epub 2019 Jun 12.

The inhibitory effect of tachyplesin I on thrombosis and its mechanisms.

Author information

Department of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang, China.
Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang, China.
Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.


Thrombotic diseases are major cause of cardiovascular diseases. This study was designed to investigate the effect of tachyplesin I on platelet aggregation and thrombosis. Platelet aggregation was analysed with a whole blood aggregometer. The mice were employed to investigate the effect of tachyplesin I on thrombosis in vivo. Tachyplesin I inhibited thrombin-induced platelet aggregation in a dose-dependent manner. Furthermore, tachyplesin I significantly reduced thrombosis in carrageenan-induced tail thrombosis model by intraperitoneal injection (0.1, 0.2 or 0.4 mg/kg) or intragastric administration (15, 30 or 60 mg/kg). Tachyplesin I also prolonged the bleeding time (BT) and clotting time (CT). The results revealed that tachyplesin I inhibited platelet aggregation and thrombosis by interfering the PI3K/AKT pathway. Tachyplesin I did not show significantly toxicity to mice under 300 mg/kg via intravenous injection. The results show that tachyplesin I inhibits thrombosis and has low toxicity. It is suggested that tachyplesin I has the potential to develop a new anti-thrombotic drug.


PI3K/Akt; anti-thrombosis; platelet aggregation; tachyplesin I


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center